NCT02064829 - Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

July 31, 2015

Conditions

Metastatic Breast CancerLocally Recurrent Breast Cancer

Interventions

DRUG

Nab-paclitaxel

260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks

DRUG

IG-001

260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks

Trial Locations (20)

37421

Sorrento investigational site, Chattanooga

38120

Sorrento investigational site, Memphis

72703

Sorrento investigational site, Fayetteville

75028

Sorrento investigational site, Flower Mound

169610

Sorrento investigational site, Singapore

Unknown

Sorrento investigational site, Batumi

Sorrento investigational site, Tbilisi

Sorrento investigational site, Chisinau

Sorrento investigational site, Bucharest

Sorrento investigational site, Belgrade

Sorrento investigational site, Kamenitz

Sorrento investigational site, Kragujevac

Sorrento investigational site, Zrenjanin

Sorrento investigational site, Cherkasy

Sorrento investigational site, Dnipropetrovsk

Sorrento investigational site, Kharkiv

Sorrento investigational site, Kyiv

Sorrento investigational site, Lviv

Sorrento investigational site, Sumy

Sorrento investigational site, Vinnytsia

All Listed Sponsors

lead

Sorrento Therapeutics, Inc.

INDUSTRY